University of Otago, Department of Pharmacology and Toxicology, School of Medical Science, PO Box 913, Dunedin, New Zealand. cynthia.darlington@stonebow.otago.ac.nz
BioMS Medical Corp, under license from the University of Alberta, is developing MBP-8298, a synthetic peptide analog of myelin basic protein, for the potential treatment of multiple sclerosis. Phase II and III clinical trials of MBP-8298 are underway.